Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC

Ebola Virus Disease Clinical Trial

— EBO-BOOST  

Official title:

Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination With the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRC: a Mix-and-match Phase II RCT

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06126822
• Other study ID #: 1706/23
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: October 2024
• Est. completion date: October 2026

Study information

• Verified date: June 2024
• Source: Institute of Tropical Medicine, Belgium
• Contact: Wim Adriaensen, Prof.
• Phone: +32(0)33455909
• Email: wadriaensen[@]itg.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this randomized controlled trial is to investigate whether individuals in DRC previously vaccinated with Zabdeno/Mvabea® or Ervebo® vaccine schedules against Ebola virus can be safely and adequately boosted with homologous or heterologous vaccine schedules.

Participants will be randomized to receive either a homologous or heterologous vaccine schedule and will be asked to come to the clinic at prespecified timepoints over a period of 6 months to collect blood samples for comparison of immunological responses against Ebola virus between both schedules. Safety and tolerability of the vaccines will be evaluated by recording Adverse Events (AE's) and grading physical and vital signs evaluations.

Description:

The aim of this randomized controlled with four arms is to investigate whether individuals previously vaccinated with Zabdeno/Mvabea® or Ervebo® vaccine schedules against Ebola virus can be safely and adequately boosted with homologous and heterologous vaccine schedules. We hypothesize that heterologous booster vaccine schedules generate a non-inferior boosting in antibodies and cellular responses against Ebola virus as compared to homologous schedules and incite a similar safety profile.

Based on the predefined variables (living place and time since vaccination), the research team will pre-select and re-contact individuals previously included in the Phase III EBOVAC vaccine database, EBOSURV participant database, and the Programme Élargi de Vaccination (PEV) database. Participants will be contacted by phone and, if they agree to participate, they are scheduled on predefined screening/recruitment days taken place at the 2 recruitment sites: INRB Goma and INRB Kinshasa.

A total of 624 participants will be included, 312 will be previously vaccinated with Zabdeno/Mvabea® and 312 participants with Ervebo®. Within those two groups, half of the participants (n=156) will be randomized to a single Ervebo® booster vaccine and the other half (n=156) to a single Zabdeno® booster vaccine. Participants will be asked to come to the clinic at prespecified timepoints over a period of 6 months to collect blood samples for comparison of antibody- and cellular response against EBOV between homologous and heterologous schedules. Safety and tolerability of the vaccines will be evaluated by recording Adverse Events (AE's) and grading physical and vital signs evaluations. An additional 50 non-vaccinated participants will be recruited in Kinshasa for assay optimization.

In case of insufficient participants living close to the recruitment centers, a community outreach will be undertaken with a lower amount of visits for logistical reasons.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 624
• Est. completion date: October 2026
• Est. primary completion date: October 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Subjects who received either the Ervebo® vaccine (MSD), or the full Zabdeno, Mvabea® vaccine regimen (J&J) more than 4 months prior to recruitment

• Subjects between 18 and 50 years of age at time of randomization

• Subject must be willing and able to provide informed consent

• The subject must be in possession of an identification card (or other identification document)

• Agreement to refrain from blood donation and other vaccinations 30 days after booster vaccination

• Agreement to share and discuss participant's medical history, medical records and concomitant medications when relevant

Exclusion Criteria:

• Participants who previously experienced active Ebola Virus Disease (EVD)

• Receipt of any vaccine (licensed or experimental) within 30 days prior to recruitment

• Receipt of an additional booster dose of either Ervebo®, Zabdeno®, or any experimental Ebola vaccine

• Incorrect or incomplete primary vaccination scheme with the Zabdeno, Mvabea® (J&J) vaccine

• Administration of immunoglobulins and/or any blood products within three months prior to recruitment.

• Fever (>38°C) within last 24 hours prior to recruitment.

• Any confirmed or suspected immunosuppressive or immunodeficient state (incl. cancer and HIV); asplenia; recurrent severe infections and use of immunosuppressant medication within the last 6 months, except topical or short-term oral steroids.

• Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder and neurological illness (mild/moderate well controlled comorbidities are allowed)

• History of anaphylaxis, allergic disease or reactions to any component of the study vaccines

• History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture

• History of any thrombotic disorder, thrombocytopenia, thrombotic thrombocytopenia syndrome (TTP), or heparin-induced thrombocytopenia and thrombosis (HITT)

• Any other significant disease, disorder, planned surgery, or finding which may significantly affect the ability of the volunteer to participate in the study or impair interpretation of the study data

• Suspected or known alcohol or drug dependency

• Subject is not readily available by telephone, email or physical address

The non-vaccinated control group will also adhere to all the above in- and exclusion criteria, with exemption of:

• Agreement to refrain from blood donation and other vaccinations 30 days after study vaccination

• Subjects who received either the Ervebo® vaccine, or the full Zabdeno, Mvabea® vaccine regimen more than 4 months prior to recruitment

The latter is rather introduced as an additional exclusion criteria:

• Subjects who received either the Ervebo® vaccine or the full Zabdeno, Mvabea® vaccine regimen

Related Conditions & MeSH terms

• Ebola Virus Disease
• Hemorrhagic Fever, Ebola
• Virus Diseases

Intervention

Drug:
• Zabdeno® booster
A single Zabdeno® booster vaccination
• Ervebo® booster
A single Ervebo® booster vaccination

Locations

Country	Name	City	State
Congo, The Democratic Republic of the	Institut National de Recherche Biomédicale (INRB)	Goma
Congo, The Democratic Republic of the	Institut National de Recherche Biomédicale (INRB)	Kinshasa

Sponsors (2)

Lead Sponsor	Collaborator
Institute of Tropical Medicine, Belgium	Institut National pour la Recherche Biomedicale (INRB)

Country where clinical trial is conducted

Congo, The Democratic Republic of the, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess non-inferiority in EBOV-specific IgG levels elicited by a heterologous to a homologous booster vaccine schedule, by type of primary vaccination, 21 days after administration of the booster.	FANG ELISA units/mL of anti-EBOV IgG	Day 21 after booster vaccination = Day 21
Secondary	To assess the safety of heterologous and homologous booster vaccine schedules, by type of primary vaccine schedule	The occurrence of solicited local Adverse Events (AEs) [Up to Day 7]; The occurrence of solicited systemic AEs [Up to Day 7]; The occurrence of unsolicited AEs [Up to Day 21]; The occurrence of Serious Adverse Events (SAE's) [Up to Month 6]	Day 7, Day 21 and Month 6
Secondary	To compare the EBOV-specific IgG levels at D21 across all vaccine combinations	- FANG ELISA units/mL of anti-EBOV IgG at D21 after vaccination	Day 21
Secondary	To compare the fold change between D0 and D21 across all vaccine combinations	- Fold change in FANG ELISA units/mL of anti-EBOV IgG between D0 and D21	Day 0 and Day 21
Secondary	To compare the EBOV-specific binding and neutralizing antibodies to the glycoproteins of different EBOV variants across all vaccine combinations and timepoints	- The Mean Fluorescence Intensity (MFI) IgG levels against the GP variants [multiplexed Luminex assay - at D0, D3, D7, D21, M6]	Day 0, Day 3, Day 7, Day 21, Month 6
Secondary	To compare the EBOV-specific binding and neutralizing antibodies to the glycoproteins of different EBOV variants across all vaccine combinations and timepoints	- The 50% neutralizing titer (NT50) levels of the GP-specific antibodies [at D0, D21, M6]	Day 0, Day 21, Month 6
Secondary	To compare the EBOV-specific effector-memory T cell response across all vaccine combinations and timepoints	- The IFN-y, TNF-a and IL-2 Spot Forming Units (SFU) after T cell stimulation with GP peptide pools [at D0, D7, D21, M6]	Day 0, Day 7, Day 21 and Month 6
Secondary	To compare the EBOV-specific effector-memory B cell response across all vaccine combinations and timepoints	- The IgG1, IgG2, IgG3 Spot Forming Units (SFU) after B cell stimulation with recombinant GPs [at D0, D7, D21, M6]	Day 0, Day 7, Day 21 and Month 6
Secondary	To characterize the phenotype and polyfunctionality of the vaccine-induced T and B cell response by vaccine combination	Proportions of EBOV GP-specific cell phenotypes and polyfunctional cells	at Day 0 and Day 21
Secondary	To assess the impact of the participant age and sex on the vaccine-induced EBOV-specific bAbs	- FANG ELISA units/mL of anti-EBOV IgG at D21 after vaccination	Day 21
Secondary	To assess the impact of the participant age and sex on the vaccine-induced EBOV-specific bAbs	- The Mean Fluorescence Intensity (MFI) IgG levels against the GP variants and VP40 [multiplexed Luminex assay - at D0, D3, D7, D21, M6]	Day 0, Day 3, Day 7, Day 21 and Month 6
Secondary	To assess the impact of the participant age and sex on the vaccine-induced EBOV-specific nAbs	- The 50% neutralizing titer (NT50) levels of the GP-specific antibodies [at D0, D21, M6]	Day 0, Day 21 and Month 6
Secondary	To assess the impact of the participant age and sex on the vaccine-induced EBOV-specific T cells	- The IFN-y, TNF-a and IL-2 Spot Forming Units (SFU) after T cell stimulation with GP peptide pools [at D0, D7, D21, M6]	Day 0, Day 7, Day 21 and Month 6
Secondary	To assess the impact of the participant age and sex on the vaccine-induced EBOV-specific B cells	- The IgG1, IgG2, IgG3 Spot Forming Units (SFU) after B cell stimulation with recombinant GPs [at D0, D7, D21, M6]	Day 0, Day 7, Day 21 and Month 6
Secondary	To assess the impact of the participant age and sex on the vaccine-induced EBOV-specific T cells	- Proportions of EBOV GP-specific cell phenotypes and polyfunctional cells [at D0, D21]	Day 0, Day 21